Dr. William Jensen

HTA assessor · NICE technical team · United Kingdom (GB) · Nephrology

Tier 2STK-0058GoodOwner MSL ABDr. Anna Becker

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: IGAN
Scientific interests: Surrogate endpointseGFR slope
Engagement preference: Virtual
Advisory boards: 1
Publications: 45
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 2: 2 per year (assumption)

Last engaged: 14 Aug 2026 (32 days ago)
Next planned contact: 13 Feb 2027
Last 6 months vs target: 100%
2 of 1 expected engagements

Insights from this stakeholder (1)

INS-0044eGFR slope interpretation
14 Aug 2026 · Access and reimbursement
CriticalAction in progress

Engagement history (2)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
14 Aug 2026	Payer / HTA meeting	Virtual	Dr. Anna Becker	Nephrada	eGFR slope interpretationProteinuria as surrogate endpoint	1	—	Reviewed	ENG-0066
06 Jun 2026	Investigator meeting	In person	Rachel Adeyemi	Vantrexa	PD-L1 testing turnaround	0	—	Reviewed	ENG-0035

Timeline

14 Aug 2026
Payer / HTA meeting
eGFR slope interpretation, Proteinuria as surrogate endpoint
06 Jun 2026
Investigator meeting
PD-L1 testing turnaround

Related stakeholders (0)

NICE technical team

No other stakeholders at this institution.